TECHBio-Techne

$72.39

The financials

Bio-Techne by the numbers

Bio-Techne (TECH) reported revenue of $311M in Q3 2026 (quarter ended March 31, 2026), down 1.5% from the same quarter a year earlier. That came with a gross margin of 67% and net income of $51M (16% of revenue). For the full year FY2025, revenue was $1.22B (+5.2% year on year) and net income $73M. Its largest region in 2026-Q1 was US at $167M, 54% of the disclosed total, just ahead of EMEA Excluding UK at 24%.

Bio-Techne income statement, Q3 2026 against the same quarter a year earlier
Income statementQ3 2026Q3 2025Change
Revenue$311M$316M−1.5%
Gross profit$208M$215M−2.9%
Operating income$75M$39M+95%
Net income$51M$23M+126%
Diluted EPS$0.32$0.14+129%
Revenue by region, 2026-Q1, as reported to the SEC
GeographicRevenueShare
US$167M54%
EMEA Excluding UK$73M24%
CN$26M8.4%
APAC Excluding Greater China$22M7.0%
GB$15M4.8%
Rest Of World$7.8M2.5%

Business Segments

Revenue split by geographic segment, from SEC XBRL filings.

Latest period: Q1 2026Total $311.4M (+5.3%)
GB grew +16% year on yearRest Of World -15% year on year
  • US$167.5MQoQ +14%year on year -7.9%
  • EMEA Excluding UK$73.4MQoQ -2.5%year on year +10%
  • CN$26.0MQoQ -1.3%year on year +6.2%
  • APAC Excluding Greater China$21.8MQoQ -4.1%year on year +2.7%
  • GB$14.9MQoQ +8.5%year on year +16%
  • Rest Of World$7.8MQoQ -30%year on year -15%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-06, SEC EDGAR